Neurogenic differentiation factor 1 (NEUROD1) (NEUROD1)

Neurogenic differentiation factor 1 (NEUROD1) is a basic helix-loop-helix (bHLH) transcription factor that serves as a critical regulator of cell fate specification and terminal differentiation in both the nervous system and the endocrine pancreas [2, 15]. In neurogenesis, NEUROD1 acts as a terminal differentiation factor and a pioneer factor, capable of remodeling the epigenetic landscape by converting closed heterochromatin to open euchromatin to initiate neuronal gene programs [15, 18]. In the pancreas, it is essential for the development and maturation of insulin-producing beta cells and directly regulates the transcription of the insulin gene by binding to E-box motifs in its promoter [1, 3, 5]. Mutations in the NEUROD1 gene are a primary cause of Maturity-Onset Diabetes of the Young type 6 (MODY6), a rare form of monogenic diabetes characterized by impaired beta-cell function and sometimes neurological symptoms [3, 8, 10]. From a therapeutic perspective, NEUROD1 is a major focus of regenerative medicine and gene therapy, particularly for treating stroke or neurodegenerative diseases by inducing in vivo neuronal reprogramming from reactive glial cells [7, 15]. Its involvement in neuroendocrine tumorigenesis also makes it a subject of research in cancers such as small cell lung cancer and neuroblastoma [6, 15].

Other names

NeuroDBETA2BHF-1bHLHa3NeuroD1Neuronal differentiation 1Class A basic helix-loop-helix protein 3

NEUROD1 acts as a transcriptional activator by forming heterodimers with ubiquitously expressed bHLH proteins (such as E47) to bind E-box motifs (5'-CANNTG-3') in the promoters of target genes including insulin, secretin, and various neuronal markers [1, 2, 19]. It also functions as a pioneer factor, binding to closed heterochromatin and recruiting co-activators like p300/CBP to remodel the epigenetic landscape (e.g., loss of H3K27me3 and gain of H3K27ac) to initiate terminal differentiation in neurons and pancreatic endocrine cells [15, 18]. Therapeutic strategies like gene therapy utilize ectopic expression of NEUROD1 to drive cellular reprogramming [7, 15].